Farmak has changed the name for corticosteroid Betaspan Depo. Now, the pharmaceutical drug is named Depos. The dosage form remains without change that is suspension for injection, 1 ml, No. 5.
Depos is prescribed for the following diseases:
Atopic dermatitis (dermatitis nummularis), neurodermatitis, contact dermatitis, apparent solar dermatitis, Urticaria, lichen ruber planus, insulin lipodystrophy, Cazenave's vitiligo, discoid lupus erythematosus, psoriasis, cicatricial keloid, pemphigus, herpetic dermatitis, cystic comedones.
Rheumatoid arthritis, osteoarthritis, bursitis, tendinous synovitis, tendinitis, peritendinitis, ankylosing spondylitis, epicondylitis, radiculitis, coccygodynia, sciatica, lumbago, torticollis, ganglion cyst, exostosis, fasciitis, acute gouty arthritis, synovial cyst, metatarsalgia, cuboid bone inflammation, feet diseases, hard corn bursitis, eperon, hallux rigidus.
Bronchial asthma, status asthmaticus, hay fever, severe allergic bronchitis, seasonal and aperiodic allergic rhinitis, angioedema, contact dermatitis, atopic dermatitis, serum disease, reaction of high sensitivity to pharmaceutical drugs or insects’ bites.
Systemic lupus erythematosus, sclerodermia, dermatomyositis, periarteritis nodosa.
Palliative care of leukaemia and lymphoma in adult patients; acute leukaemia in children.
Androgenital syndrome. Ulcerative colitis, Crohn's disease, aphthous cachexia. Pathologic changes in blood requiring corticosteroid therapy. Nephritis, nephritic syndrome.
Primary and secondary insufficiency of cortex glandula suprarenalis (with mandatory simultaneous injection of mineralocorticoids).
On July 15, 2020 the first Voluntary National Review of progress towards the Sustainable Development Goals was presented by Ukraine to the world community. The UN Global Compact Network Ukraine prepared the Review of Business Progress in Ukraine towards the Sustainable Development Goals which included Farmak, the only company representing the Ukrainian phar...
Farmak increased manufacturing capacity by 35% and reduced gas and electricity consumption by 76% and 64% respectively for 5 years, emission release is annually reduced by an average of 12-20% over this period This is stated in Farmak’s non-financial report on corporate social responsibility which the Company has prepared in accordance with the commitments t...
The book Visionary (in Ukrainian: Vizioner («Візіонер»)) about Filya Zhebrovska, the owner of the largest Ukrainian pharmaceutical company Farmak, was published in April by Burda Publishing House. The biography tells about the life of a person who managed to steer the Soviet enterprise out of the crisis and transform it into a modern European manufacturing [...